跳至主要内容
临床试验/NCT00693485
NCT00693485已完成2 期

Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

Allergan0 个研究点目标入组 70 人开始时间: 2008年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Allergan
入组人数
70
主要终点
Percentage of Patients With a Visual Field Improvement in the Study Eye

研究概览

简要总结

A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Primary open-angle glaucoma in one eye
  • Visual acuity 20/80 or better
  • Intraocular pressure in the study eye ≤ 24 mm Hg
  • Glaucomatous visual field loss - 7 dB to - 25 dB

排除标准

  • Known allergy to brimonidine tartrate
  • Uncontrolled systemic disease or infection of the eye
  • Recent eye surgery or injections in the eye
  • Female patients who are pregnant, nursing or planning a pregnancy

研究组 & 干预措施

400 ug Brimonidine Implant

Experimental

400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

干预措施: 400 ug Brimonidine Implant (Drug)

200 ug Brimonidine Implant

Experimental

200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

干预措施: 200 ug Brimonidine Implant (Drug)

Sham (no implant)

Sham Comparator

Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

干预措施: Sham (no implant) (Drug)

结局指标

主要结局

Percentage of Patients With a Visual Field Improvement in the Study Eye

时间窗: Baseline, Month 6

Visual field improvement in the study eye is determined using the Humphrey Field Analyzer (HFA 24-2) full threshold test and clinical expertise. The Humphrey Field Analyzer is a machine that helps to map the field (peripheral) of vision. An improvement is an increase in the field of vision. The percentage of patients with a visual field improvement in the study eye is reported.

次要结局

  • Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye(Baseline, Month 6)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验

Safety and Effects of Brimonidine Intravitreal... | 临床试验